CS Paper Radar

AgentFold: Closed-Loop Agentic Search for Protein Folding Model Design

Mingquan Liu, Jiangyu Chen, Hanqun Cao, Xujun Zhang, Pengsen Ma, Xiangru Tang, Shuting Jin, Zhuo Yang, Annie Zheng, Tianfan Fu, Fang Wu, Xiangxiang Zeng

cs.AI ·submitted 2026-08-27 07:38 UTC · v2
top venuecode/data

Abstract

Scientific LLM agents have shown promise in literature reasoning, tool use, and experiment planning, but it remains unclear whether they can autonomously improve large, tightly coupled scientific machine-learning systems through executable code changes and computationally expensive validation. We study this question in protein folding, where progress requires coordinated architectural modifications, multi-objective evaluation, and domain-aware interpretation. We present AgentFold, a multi-agent framework that formulates folding-model development as a closed-loop search over executable code variants. Starting from ESMFold, AgentFold proposes hypotheses, implements and debugs code-level modifications, evaluates model variants, analyzes experimental outcomes, and stores both successful and failed interventions in structured memory. An MCTS-style policy allocates computational resources across high-scoring search branches. On an engineering-scale protein-folding codebase comprising more than 2,000 lines of code, AgentFold explores approximately 80 model variants using approximately 5,000 GPU-hours and 170 million LLM tokens. Under a matched computational budget, AgentFold improves the best lDDT by 7.5% over independent Codex proposals and outperforms a random-search control. Beyond model improvement, the resulting intervention traces reveal recurring empirical design patterns: stable gains tend to arise from early, soft, learnable priors and gated refinement, whereas direct geometric perturbations and geometry-conditioned feedback often destabilize training. The code and experimental resources are publicly available at https://github.com/lmqfly/AgentFold.

Closest papers

Nearest neighbours by meaning across the whole index.

ReproBAIT: Can coding agents build their own biological AI tools?

cs.AI cs.CYcs.LG ·2026-10-14 ·Shiv Muthupandiyan, Tolga H. Dur, Mac Walker, Timo Flesch, Mahmoud Ghanem +6 more
code/data similarity 0.78
Abstract

Large language models are increasingly competent at leveraging scientific knowledge and existing computational tools to execute complex workflows. At present, little information exists on their ability to reconstruct tools when given limited descriptions of such tools. We introduce an evaluation titled ReproBAIT (Reproducing Biological AI Tools), which measures the ability of coding agents to design, implement, and train biological AI tools taken from published research across a range of information access conditions. The coding agent is securely sandboxed without internet access and receives training data, a fixed time and compute budget, and limited information about the tool to replicate. We then score the reproduced biological AI tool based on its performance (tool-specific metrics) on held-out data. We evaluated a set of biological AI tools of varying complexities: ProteinMPNN, an inverse protein folding tool, RFdiffusion3, an all-atom generative diffusion tool, and a closed-source molecular design tool. We institute a methodology to check for memorisation, as the open source tools are likely to be included in models' pretraining corpus. Across a range of leading closed- and open-source coding agents, we find substantial reproduction capability for some selected tools, though limited capability for a highly complex tool. We find moderate evidence consistent with memorisation, varying across coding agents. These results suggest that tool developers need to be increasingly cautious when releasing information about the tools publicly; re-creation of the tool based on such information could undermine a tool's commercial value or invalidate dual-use managed access strategies.

0.47

Agentic BAIM-LLM Evaluation (ABLE): Benchmarking LLM Use of Protein Design Tools

cs.AI cs.CYq-bio.QM ·2026-09-05 ·Bryce Cai, Geetha Jeyapragasan, Samira Nedungadi, Jake Yukich, Seth Donoughe
publishedbenchmarkhighly cited similarity 0.74
Abstract · Last revised in February 2026; presented without further revision. An earlier revision at was presented at the NeurIPS 2025 Workshop on Bios…

We introduce ABLE, a benchmark for evaluating LLM agents' ability to use biological AI models (BAIMs), such as ProteinMPNN and AlphaFold3, in dual-use protein design workflows. ABLE assesses agent performance through a set of tasks spanning structure retrieval, sequence generation, and design validation. We evaluate 15 frontier models and find that seven refuse all tasks, while the remaining models exhibit substantial performance differences. Claude Sonnet 4 and Gemini 3 Pro achieve the highest scores across information retrieval, tool selection, and tool use. We further compare model performance on a subset of tasks against an expert human baseline. Our results suggest that current LLMs can substantially lower barriers to protein design, but remain inconsistent in planning, strategy generation, and integrating biological knowledge with tool use.

0.57

BioXArena-Pro: a research-grade benchmark for autonomous biomedical machine learning agents

cs.LG ·2026-11-10 ·Loka Li, Duzhen Zhang, Xingbo Du, Leonard Song, Kun Zhang +1 more
benchmarkcode/data similarity 0.69
Abstract · 51 pages (22 main text, 29 supplementary information), 5 figures, 7 supplementary tables. Code: https://github.com/mbzuai-ai4bio/BioXArena-P…

Coding agents are increasingly proposed as autonomous builders of biomedical models, but existing benchmarks are small, near saturation or open to leaked information. We present BioXArena-Pro, 64 research-level modelling tasks from eight biomedical domains, each rebuilt from a published study; most hold out whole biological units such as species or cohorts. Across 22 agent configurations, the best scores 55.1 of 100, and the scaffold matters almost as much as the model. We re-ran a published method for every task: where the published recipe applies unchanged, the best agent and the methods tie; on rebuilt tasks the methods trail by 8.2 points, suggesting that agents gain by adapting to new data. Pretrained models (including biological foundation models) matter where the strongest agent uses them: forbidding them decreases its score on those tasks by 9 points. Every task was audited in several AI-assisted rounds and a final human review.

0.27

DrugCoding: A Scientific Programming Agent for Drug Discovery

cs.AI cs.MA ·2026-11-10 ·Junwei Hu, Zhuohao Lin, Kun Li, Hengnan Zhang
benchmark similarity 0.69
Abstract

Drug discovery involves multiple interconnected research stages, including molecular design, property prediction, and virtual screening. These processes are characterized by complex workflows, interdependent computational tasks, and diverse specialized tools, placing substantial demands on the coordination of scientific models and computational resources. However, existing large language model (LLM)-based scientific agents still face challenges in autonomous planning of complex tasks, adaptive selection of specialized models, and reliable execution of multi-stage scientific computations, limiting their effectiveness in automating complex drug discovery workflows. To address these challenges, we propose DrugCoding, a scientific programming agent system that integrates scientific task planning, adaptive model routing, multi-agent collaboration, and programmatic tool execution. DrugCoding enables autonomous task planning and dynamic model adaptation for complex research objectives. It can flexibly invoke specialized scientific models, autonomously generate and execute code according to task requirements, and leverage multi-agent collaboration to support efficient execution and reliable validation of complex scientific tasks. To evaluate DrugCoding's performance in scientific tool invocation and multi-stage task execution, we conduct multi-turn tool-calling experiments across diverse language models and scientific tool interfaces. Experimental results demonstrate that DrugCoding achieves an average session-level Pass@1 of 97.35% on the full benchmark, outperforming the strongest baseline, Codex, by 9.24%. On the challenging subset, DrugCoding achieves 97.92%, exceeding the strongest baseline.

0.14

KnowEvo: Knowledge Evolution for Protein Optimization

cs.LG ·2026-11-06 ·Zijie Xing, Xingyue Liu, Runze Wang, Luoming Hu, Yanming Shen
top venuecode/data similarity 0.68
Abstract · Accepted by NeurIPS 2026

Large language models (LLMs) have shown promise in scientific discovery, yet systematically accumulating and refining reusable scientific knowledge remains challenging. Existing approaches primarily improve LLM-based problem solving through parameter optimization or feedback-driven refinement of prompts, programs, and solution trajectories, leaving acquired expertise either embedded in model weights or scattered across iterative problem-solving processes. As a result,knowledge is difficult to systematically inspect, evaluate, and refine. We propose KnowEvo, a framework that treats externalized knowledge itself as the optimization target. Our key insight is that scientific knowledge is inherently modular: multiple interacting mechanisms jointly determine the design outcomes. This makes knowledge evolution fundamentally challenging, as improvements cannot be attributed to individual components in isolation. To address this, KnowEvo represents knowledge as executable expertise blocks and organizes their refinements into strategy mutation trees, enabling structured exploration over a combinatorial knowledge space. The framework combines a Thompson-style forward allocation strategy that adaptively distributes evaluation budgets across strategy variants with a backward revision process, in which a code agent operates in an isolated sandbox to translate rollout evidence into localized program updates. This design enables persistent accumulation, evaluation, and refinement of mechanistic expertise across iterative experimentation. We evaluate KnowEvo on protein optimization tasks including stability and solubility. Results show that knowledge evolution consistently improves over initial strategy blocks and outperforms monolithic program evolution and prior LLM-guided evolution baselines across metrics such as pass@k, MRR, MAP,and NDCG@5. Code is available at https://github.com/recynie/KnowEvo.

0.33

El Agente Fármaco: A Scalable AI Scientist for Drug Discovery

cs.AI cs.MAq-bio.BM ·2026-11-02 ·Marcel Müller, Mohammad Ghazi Vakili, Yoshihiro Ogura, Ella Ashoori, Shimeng Wang +11 more
benchmark similarity 0.68
Abstract · 63 pages, 13 figures, including Supporting Information

Computational drug discovery offers a growing range of tools for proposing and evaluating molecules, but combining them and deciding what to do next still requires substantial expert effort. Here, we introduce El Agente Fármaco, an AI scientist that uses modern large language model (LLM) technology to turn discovery goals expressed in everyday language into complex, scalable computational screening workflows. The agentic harness selects scientific tools, reviews their results, and adjusts subsequent steps to the target and the user's objectives. Our approach centers on a shared scientific memory: Fármaco Atlas, which stores molecules, structures, and results together with their provenance -- a record of how they were obtained. The agent uses targeted database queries to retrieve the evidence needed for each decision. A single request can launch calculations for an entire collection of molecules, without requiring a separate LLM decision for every compound. This design limits the information the model must process as screening collections grow, while keeping the underlying results available for inspection and further analysis. The integrated tools support molecule generation, prediction of binding and molecular properties, and searches for compounds available for purchase. In a retrospective comparison with an expert-led campaign, the agent proposed chemically distinct candidates with competitive docking scores and higher calculated drug-likeness under explicitly imposed selection criteria. In a 22-task benchmark against plain tool calls and Codex, the agent achieved the highest observed mean model-judged score, with lower median cumulative token use and peak context. Fármaco provides a foundation for flexible, scalable drug discovery workflows that connect scientific reasoning with an enduring, traceable record of computational work.

0.08

BioDyad: Synchronize Biomedical Discovery and Machine Learning Engineering

cs.AI ·2026-09-25 ·Xingbo Du, Fadli Aulawi Al Ghiffari, Leonard Song, Loka Li, Duzhen Zhang +3 more
benchmark similarity 0.67
Abstract · 19 pages, 6 figures

Agentic biomedical machine learning (ML) draws on complementary advances in biomedical evidence acquisition and executable program search. Existing systems connect aspects of these capabilities, but coordinating them throughout program search remains challenging. New evidence must guide candidate construction, execution outcomes must inform subsequent discovery and reuse, and validation demands must fit the search budget. We introduce BioDyad, which couples biomedical discovery and ML engineering through two hierarchies within Monte Carlo graph search. Its scientific hierarchy combines prior biomedical guidance with iterative discovery, then links biomedical plans to execution outcomes in memory for reuse across candidates. Its engineering hierarchy moves candidate programs from smoke execution, through train/validation evaluation, to full-data retraining. We evaluate BioDyad on the 76-task BioXArena benchmark under a two-hour per-task budget with three matched LLM backends. It achieves the highest penalized all-task score and task success rate among four agent methods and a one-shot baseline under each backend. These results support coordinating biomedical discovery and ML engineering to integrate external knowledge into executable programs across heterogeneous biomedical tasks.

0.36

MoLRSI: A Recursive Self-Improving AI agent for Molecular Discovery

cs.AI ·2026-10-29 ·Yikun Zhang, Xiwei Cheng, Mingze Yuan, Yu Zhang, Brian Shim +13 more
community pick similarity 0.67
Abstract · v2: updated the author list

Molecular discovery requires navigating vast combinatorial search spaces while balancing competing biological objectives. AI agents can automate expert-defined molecular design protocols, but automation alone does not address how to optimize workflows for new tasks or improve their development through experience. Here we introduce MoLRSI, an AI agent that combines systematic optimization of workflows and model architectures with persistent cross-task memory to recursively improve its search policy for molecular discovery. Workflow performance, refinement outcomes, and execution feedback guide subsequent searches, allowing the agent to improve both its workflows and its strategy for developing them. We evaluate MoLRSI in two challenging molecular discovery settings that require balancing competing properties. In antibiotic discovery, MoLRSI developed a screening workflow balancing antibacterial activity, cytotoxicity and structural novelty, achieving an experimental hit rate of 15.9%, compared with 8.7% for a previous expert-led workflow using the same training data and screening library. In de novo peptide-MHC binder design, MoLRSI developed workflows that jointly consider target binding and specificity, producing eight experimentally validated hits against MART-1 and SARS-CoV-1 pMHCs with preferential binding over tested off-targets while Claude Science completely failed. These findings demonstrate how experience-guided workflow optimization can address competing discovery objectives while improving the search strategies used in subsequent campaigns.

0.39